

Our ref: IG/FOI/FOI.474.25

04 September 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 20 August 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require.

For ease of reference your request is set out below and my response follows.

Your Freedom of Information (FOI) Request:

Under the Freedom of Information Act 2000, please provide the following recorded information held by your Integrated Care Board regarding use of bevacizumab gamma (Lytenava®) for neovascular (wet) age-related macular degeneration (NICE TA1022):

Scope & period

1. 1 June 2025 – 30 June 2025
2. 1 July 2025 – 31 July 2025

Information requested (for each month above):

Q1. Total number of Blueteq prior-approval forms submitted for bevacizumab gamma (Lytenava) for wet AMD within your ICB.

Please split totals into:

- a) Initiation forms (treatment starts)
- b) Continuation forms (ongoing approvals / renewals)
 - If held, please also provide a breakdown by provider Trust within your ICB.

Format & identifiers

- Please provide the data in CSV or XLSX.

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

- Drug identifiers for clarity: bevacizumab gamma (brand: Lytenava®; NICE TA1022; if useful for your systems, PIP code often referenced is 1215680).

Notes

- I am requesting aggregate figures only; no patient-level data are required.
- If your ICB does not hold some or all of this information but your provider Trusts do, please advise and/or transfer this request to the relevant bodies under the FOI Section 45 Code of Practice.
- If any figure is ≤ 5 and you consider disclosure risky to anonymity, please use standard rounding/redaction (e.g., " ≤ 5 ").


Powys Response:

I can confirm that the All-Wales Blueteq forms for health board commissioned ophthalmology therapies has not yet been developed, therefore they cannot be submitted for bevacizumab gamma (Lytenava).

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via Powys.FOI@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.